Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by attacking two essential parasite pathways. Atovaquone blocks the mitochondrial electron transport chain, halting ATP production, while proguanil is converted to cycloguanil, which inhibits dihydrofolate reductase, disrupting folate metabolism. This dual action produces synergistic parasite killing and reduces resistance development.

The prescribed dose of Malarone is set by the treating clinician based on the indication (prevention or treatment), the patient’s age, weight, renal and hepatic function, and local resistance patterns. Patients should follow the exact dosing schedule provided by their healthcare professional.

Malarone is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data exist for breastfeeding; a risk‑benefit assessment should be performed by the prescriber.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies such as chloroquine or mefloquine, Malarone offers a broader spectrum against chloroquine‑resistant strains and a lower incidence of neuropsychiatric side effects. Its dual‑mechanism reduces the chance of resistance, but it may be more expensive and requires adherence to a daily dosing schedule.

Malarone tablets should be stored at temperatures below 25 °C, in their original blister pack, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Malarone is taken orally with food or a milky drink to improve absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area, taken once daily throughout the stay, and continued for 7 days after leaving. For treatment, the regimen is prescribed by a clinician and typically continued for three days.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, hemolytic anemia (especially in G6PD‑deficient individuals), and hypersensitivity reactions that may progress to anaphylaxis. Patients should seek immediate medical attention if they develop rash, jaundice, fever, or unexplained bleeding.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in those with G6PD deficiency when risk of hemolysis is a concern.